Atorvastatin
Prescription cholesterol-lowering medicine (a statin) that also lowers the risk of heart attack and stroke.

Related comparisons
Atorvastatin vs RosuvastatinDETAILED OVERVIEW
What is Atorvastatin?
Atorvastatin is a prescription cholesterol-lowering medicine from the statin group. It is used for high cholesterol and to prevent heart attack and stroke, for example in people who have already had one, and in people with diabetes.
It blocks cholesterol production in the liver, so the liver removes more LDL (“bad” cholesterol) from the blood, and LDL can fall by 30–60%. Large studies show that this lowers the risk of heart attack, stroke and death from heart and blood vessel disease. Muscle pain and weakness can occur; rarely a severe muscle injury develops that can lead to kidney failure, more likely with strong drug interactions or regular grapefruit juice. It can raise liver enzymes and slightly raises the chance of developing diabetes. It must not be used in pregnancy or breastfeeding, because cholesterol is needed for the baby's development.
ATC code
C10AA05
Prescription
Prescription only (Rx)
Mechanism
HMG-CoA reductase inhibitor (statin)
Half-life
14 h (active metabolites 20-30 h)
LDL reduction
50–60% with the strongest form of treatment
No anecdote collected yet.
Data console
Lab data
LaRosa JC, Grundy SM, Waters DD et al. . Intensive lipid lowering with atorvastatin in patients with stable coronary disease (TNT). N Engl J Med. 2005;352(14):1425-35..
Colhoun HM, Betteridge DJ, Durrington PN et al. . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes (CARDS). Lancet. 2004;364(9435):685-96..
Amarenco P, Bogousslavsky J, Callahan A 3rd et al. . High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med. 2006;355(6):549-59..
Baigent C, Blackwell L, Emberson J et al. . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis (CTT). Lancet. 2010;376(9753):1670-81..
Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG . Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome.. Eur J Prev Cardiol.
Sever PS, Dahlöf B, Poulter NR et al. . Prevention of coronary and stroke events with atorvastatin (ASCOT-LLA). Lancet. 2003;361(9364):1149-58..
Grundy SM, Stone NJ, Bailey AL et al. . 2018 AHA/ACC/Multisociety guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143..
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Muscle pain, myalgia and weakness (statin-associated muscle symptoms, SAMS), typically symmetric and proximal; dose-dependent, more common at 80 mg.
- Rare but serious: rhabdomyolysis (CK >10x ULN + myoglobinuria) that can cause acute kidney injury; risk increased when combined with CYP3A4 inhibitors or fibrates.
- Elevation of liver transaminases (ALT/AST), usually reversible and dose-dependent; persistent rise >3x ULN warrants dose reduction or discontinuation.
- Slightly increased risk of new-onset type 2 diabetes (about 9–12% relative), mainly in prediabetic patients; cardiovascular benefit outweighs this.
- Gastrointestinal complaints: nausea, diarrhea, constipation, abdominal discomfort, dyspepsia.
- Headache, nasopharyngitis, joint pain (arthralgia) and pain in extremities, among the common, generally mild adverse effects.
- Very rare: immune-mediated necrotizing myopathy (anti-HMGCR antibodies), which can persist after stopping the statin and requires immunosuppression.
Contraindications · 4
- Active liver disease or persistent unexplained ALT elevation (>3x ULN)
- Pregnancy and lactation (lipid synthesis needed for embryonic development)
- Concomitant strong CYP3A4 inhibitor use (clarithromycin, itraconazole, ritonavir)
- Active rhabdomyolysis or CK elevation > 10x ULN
Related Pharmaceuticals
Same therapeutic category
Studies
Related research and clinical findings
Intensive lipid lowering with atorvastatin in patients with stable coronary disease (TNT)
LaRosa JC, Grundy SM, Waters DD et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes (CARDS)
Colhoun HM, Betteridge DJ, Durrington PN et al.
High-dose atorvastatin after stroke or transient ischemic attack (SPARCL)
Amarenco P, Bogousslavsky J, Callahan A 3rd et al.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis (CTT)
Baigent C, Blackwell L, Emberson J et al.
Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome.
Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG
Prevention of coronary and stroke events with atorvastatin (ASCOT-LLA)
Sever PS, Dahlöf B, Poulter NR et al.
2018 AHA/ACC/Multisociety guideline on the management of blood cholesterol
Grundy SM, Stone NJ, Bailey AL et al.
Telegram
Have a question about Atorvastatin?
Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.